Services

Therapeutic Antibody Overview

Introduction

It has been more than one hundred years from antibody’s first discovery in blood serum to the current therapeutic antibody development. Antibody structure and antibody function is well known, so it won’t be repeated in this overview.

What Are Therapeutic Antibodies?

Therapeutic antibodies are biopharmaceuticals widely used in the treatment of cancer, autoimmunity, and inflammatory diseases or for drug delivery to target antigen, most of which are monoclonal antibodies. Therapeutic antibody recognizes and binds to the antigen receptor to activate or inhibit a series of biological process for blocking cancer cell growth or triggering immune system. The mechanism of action (MOA) between therapeutic antibody and small molecule pharmaceutical is dramatically different, even though both of them target the same antigen site. Compared to small molecule pharmaceutical, therapeutic antibody possesses characteristic properties of high affinity, high specificity, and low immunogenicity, as it is essentially a monoclonal antibody that can recognize and bind to a unique epitope. Early monoclonal antibody (mab) was generated by fusing myeloma cell and spleen cells to obtain hybridoma secreting mab. Early therapeutic antibody was usually produced in murine host, leading to serious human anti-mouse antibody expression called HAMA reaction, which in turn interfered with the therapeutic effects. While, the disadvantages of short half-life, xenogenicity and limited activity were gradually improved with the development of gene engineering, in vitro cell culture technology and the deeper understanding of each antibody fragment function. In the past four decades, therapeutic antibodies have made great improvement in antibody engineering. Below is a timeline of important technologies for engineering therapeutic antibodies and representative approved biopharmaceuticals (Fig. 1).

Timeline of Therapeutic Antibody Development

Fig. 1. Timeline of Therapeutic Antibody Development

Development Process of Therapeutic Antibodies

Benefiting from the advances of antibody engineering technologies, immunogenicity of therapeutic antibody is rapidly reduced. According to different immunogenicity, therapeutic antibody can be divided into four stages, consisting of murine antibody, chimeric antibody, humanized antibody and fully human antibody. Fig. 2 shows these four types of therapeutic antibodies, among which chimeric antibody has the highest immunogenicity.

Formats of Therapeutic Antibody

Fig. 2. Formats of Therapeutic Antibody

1. Murine Antibodies

The era of therapeutic antibody emerged from hybridoma technology, generating monoclonal antibody targeting a unique epitope. In 1975, Kohler and Milstein introduced an in vitro cultured hybridoma secreting anti-sheep red blood cell monoclonal antibody by fusing mouse myeloma cell and mouse spleen cells. This hyriboma overcame the problem of B cells in vitro culture, which helped Kohler and Milstein win the Nobel Prize of Physiology or Medicine in 1984. 11 years after the appearance of hybridoma technology, FDA approved the first therapeutic antibody, anti-CD3 muromomab, a murine monoclonal antibody. Unexpectedly, with the increasing number of patients treated with murine monoclonal antibody, terrible side-effect appeared. Human immune system recognized murine monoclonal antibody as a foreign antigen that induced HAMA reaction, which shortened the half-life of murine monoclonal antibody in human serum. Moreover, murine monoclonal antibody Fc fragment did not interact with complementary system or effector cells to activate CDC or ADCC effector function. In the following years, considerable efforts were devoted to genetically engineering monoclonal antibodies in order to make them less immunogenicity.

2. Chimeric Antibodies

The second generation of therapeutic antibody is chimeric antibody. In 1984, Morrison firstly introduced chimeric antibody using recombinant DNA technology, joining mouse antibody variable region gene to human antibody constant region gene. The constructed chimeric vector was transfected into mouse myeloma cells and the cells expressed chimeric antibodies. Combining the mouse variable region with human constant region improved the monoclonal antibody humanization proportion to 70%, which reduced HAMA. In 1994, the first chimeric therapeutic antibody abciximab, Fab formats, was approved by FDA for inhibiting platelet aggregation by binding platelet glycoprotein Ⅱb/Ⅲa receptor. In 1997, the first full-length IgG chimeric therapeutic antibody rituximab was approved for treatment of non-hodgkin’s lymphoma and rheumatoid arthritis. Chimeric formats therapeutic antibody achieved greatersuccess than murine therapeutic antibody because of its lower immunogenicity and effective Fc effector function, which encouraged people to fight against cancer and autoimmune diseases by focusing on therapeutic antibody development.

3. Humanized Antibodies

In order to further improve humanization proportion, humanized antibody was developed by researchers. In 1986, Jones provided a method for reducing immunogenicity brought by humanized antibody's framework region through grafting complementarity-determine region (CDR) from mouse antibody into corresponding region of human antibody. This method was widely used with a modification in later humanized therapeutic antibody research and development. Humanized therapeutic antibody improved humanization proportion to 85%-90%. The first approved humanized therapeutic antibody is anti-CD25 daclizumab used in the treatment of adults with relapsing forms of multiple sclerosis. Nowadays, chimeric antibody and humanized antibody are main formats of human therapeutic antibody and play an important role in cancer therapy.

4. Fully Human Antibody

Another stage of therapeutic antibody is fully human antibody which benefits from the development of two technologies. The first one is in vitro screening technology–phage display. In 1990, Greg Winter`s laboratory introduced this new technology by amplifying immunoglobulin variable region from hybridomas or B cells and cloning into expression vector. Phages carrying complete variable region gene displayed protein expressed by antibody variable region on their surface, then they could be selected directly by specific antigen. Once expressed variable region protein binding the specific antigen was selected, its gene is immediately available, allowing sequencing of phage clone and further manipulation, which made it possible to rapidly and effectively select fully human antibody. Another technology is transgenic mouse replacing the whole mouse IgG repertoire with a human one. The transgenic mouse is immunized with specific antigen, then high affinity antibody can be generated through hybridoma technology. Compared to phage display, transgenic mouse has obvious advantages. They do not need additional affinity maturation procedure. Moreover, a full-length IgG is directly generated, which is often the preferred format of therapeutic antibody. However, if the antigen is toxic, the phage display may be a better choice. In 2002,12 years after the first description of phage display technology, the first fully human antibody approved by FDA was adalimumab which achieved huge success with a wide range of indications.

Therapeutic Monoclonal Antibodies Approval and Revenue

In pharmaceutical industry, therapeutic antibodies are now being uses as important drug modalities. Recently, significant work is being carried out by scientists to revolutionize the antibodies production technique and to develop complex monoclonal antibodies based therapies (bispecifics, brain penetrant monoclonal antibodies and monoclonal antibodies mixture) in order to address noteworthy medical needs. The development of therapeutic monoclonal antibodies is the fastest in the field of drug discovery and development, and therapeutic monoclonal antibodies have brought new hope for the treatment of diseases such as cancer, immune disease. As of January 2017, the FDA has approved 68 therapeutic monoclonal antibodies for the treatment of different indications (as shown in table 1). Therapeutic monoclonal antibodies have shown an unprecedented pace of development. Only three therapeutic monoclonal antibodies were approved in 2013, and four in 2014. While, the FDA historically approved 10 therapeutic monoclonal antibodies in 2015. In 2016, 10 therapeutic monoclonal antibodies were also approved. It is notable that market revenue of therapeutic monoclonal antibodies is increasing year by year. Therapeutic monoclonal antibody occupies 5 of the top 10 best-selling biological agents. The highest revenue of therapeutic monoclonal antibody is Humira from AbbVie, more than 16 billion dollar in 2016. While, three products of therapeutic monoclonal antibodies from Roche are in the list of these 5, namely Rituxan, Avastin, Herceptin.

Table 1. FDA Approved Therapeutic Antibodies

International Non-proprietary Name Trade name International Non-proprietary Name Trade name
Muromonab-DC3 Orthoclone OKT3® Denosumab Prolia®
Satumomab OncoScint® Belimumab Benlysta®
Abciximab ReoPro® Brentuximab Adcetris®
Nofetumomab Verluma® Denosumab Xgeva®
Imiciromab MyoScint®(Diagnostic) Ipilimumab Vervoy®
Capromab ProstaScint®(Diagnostic) Pertuzumab Perjeta®
Arcitumomab CEA-scan®(Diagnostic) Raxibacumab ABthrax®
Rituximab Rituxan®MabThera® Obinutuzumab Gazyva®
Daclizumab Zenapax® Trastuzumab Kadcyla®
Basiliximab Simulect® Siltuximab Sylvant®
Infliximab Remicade® Ramucirumab Cyramza®
Palivizumab Synagis® Blinatumomab Blincyto®
Trastuzumab Herceptin® Pembrolizumab Keytruda®
Gemtuzumab Mylotarg® Vedolizumab Entyvio®
Adalimumab Humira® Secukinumab Cosentyx®
Alemtuzumab Campath® Nivolumab Opdivo®
Ibritumomab tiuxetan Zevalin® Dinutuximab Unituxin®
Efalizumab Raptiva® Alirocumab Praluent®
Omalizumab Xolair® Idarucizumab Praxbind®
Tositumomab and iodine 131 tositumomab Bexxar® Evolocumab Repatha®
Bevacizumab Avastin® Daratumumab Darzalex®
Cetuximab Erbitux® Mepolizumab Nucala®
Fanolesomab NeutroSpec®(Diagnostic) Necitumumab Portrazza®
Natalizumab Tysabri® Elotuzumab Empliciti®
Catumaxomab Proximium® Obiltoxaximab Anthim®
Panitumumab Vectibix® Ixekizumab Taltz®
Ranibizumab Lucentis® Reslizumab Cinqair®
Eculizumab Soliris® Atezolizumab Tecentriq®
Certolizumab pegol Cimzia® Daclizumab Zinbryta®
Canakinumab Ilaris® Adalimumab-Atto Amjevita®
Golimumab Simponi® Ustekinumab Stelara®
Ofatumumab Arzerra® Atezolizumab Tecentriq®
Tocilizumab Actemra® Olaratumab Lartruvo®
Ustekinumab Stelara® Bezlotoxumab Zinplava®

References:
1. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity[J]. Nature, 1975, 256(5517): 495-497.
2. Morrison S L, Johnson M J, Herzenberg L A, et al. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains[J]. Proceedings of the National Academy of Sciences, 1984, 81(21): 6851-6855.
3. McCafferty J, Griffiths A D, Winter G, et al. Phage antibodies: filamentous phage displaying antibody variable domains[J]. nature, 1990, 348(6301): 552-554.

Online Inquiry
Please input "biolabs"(case insensitive) as verification code.
45-1 Ramsey Road, Shirley, NY 11967, USA     Tel: 1-631-381-2994    Fax: 1-631-207-8356    Email:
Terms of Service-Privacy Policy     © 2007 - 2018 Creative-Biolabs All Rights Reserved